Wegeners granulomatosis secondary prevention

Granulomatosis with polyangiitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Granulomatosis with polyangiitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Wegeners granulomatosis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Wegeners granulomatosis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Wegeners granulomatosis secondary prevention
CDC on Wegeners granulomatosis secondary prevention
Wegeners granulomatosis secondary prevention in the news
Blogs on Wegeners granulomatosis secondary prevention
Directions to Hospitals Treating Granulomatosis with polyangiitis
Risk calculators and risk factors for Wegeners granulomatosis secondary prevention

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Secondary Prevention

General well-being and laboratory organ markers are checked on a regular basis to ascertain the patient has remained in remission.